Jam

Visionary Holdings Inc. received a Nasdaq notification on August 5, 2025, for non-compliance with Listing Rule 5250(c)(1) due to a delayed Form 20-F filing. Visionary submitted a compliance plan on October 6, 2025, and is working with its auditor to expedite the filing. The company is committed to Nasdaq listing. Analysts note that reporting delays can raise investor concerns, while Visionary’s tech-focused model may contribute to audit complexities. The company must address the delay to maintain investor confidence and avoid potential delisting.

BridgeBio Oncology Therapeutics announced positive preclinical data for BBO-10203, a novel compound selectively disrupting the RAS:PI3Kα interaction crucial for KRAS-mutant tumor growth. BBO-10203 inhibits RAS-driven PI3Kα-AKT signaling without causing hyperglycemia. In vivo studies showed oral bioavailability and significant anti-tumor activity, with deep tumor regressions when combined with BridgeBio’s KRAS inhibitors. BBO-10203 is currently in Phase 1 trial (BREAKER-101), and initial Phase 1 clinical data is expected in H1 2026.

Cullinan Therapeutics will present preclinical data on CLN-978, a CD19xCD3 bispecific T cell engager, at ACR Convergence 2025. Studies show CLN-978 rapidly depleted B cells in samples from RA, Sjögren’s, and SLE patients, and in nonhuman primates after subcutaneous dosing. In a SLE mouse model, it reduced B cells, anti-dsDNA IgG, and kidney IgG deposition. Cullinan is advancing CLN-978 in OUTRACE clinical programs for RA, SjD, and SLE.

Phathom Pharmaceuticals’ VOQUEZNA (vonoprazan) demonstrated rapid and sustained relief of nocturnal GERD symptoms in a Phase 3 trial. Patients experienced significantly more heartburn-free nights compared to placebo, with symptom relief starting after the first dose and lasting through a 20-week extension. VOQUEZNA was generally well-tolerated, though the label includes postmarketing risks requiring monitoring. Some efficacy analyses were exploratory and not adjusted for multiple comparisons. VOQUEZNA is approved in the US for GERD and *H. pylori* treatment.

Harvard Ave Acquisition Corporation (HAVAU) closed its $145 million IPO, offering 14,500,000 units at $10.00 each. Units, trading on Nasdaq under HAVAU since October 23, 2025, consist of Class A ordinary shares and rights, expected to list as HAVA and HAVAR, respectively. The Cayman Islands-based SPAC, managed by D. Boral Capital, will pursue a business combination. Investors should note the risks inherent in SPACs, including target selection and regulatory scrutiny.

American Riviera Bancorp (OTCQX: ARBV) reported a net income of $2.9 million ($0.51/share) for Q3 2025 and $7.9 million ($1.38/share) for the nine months ended September 30, 2025. Total deposits rose 11.3% to $1.26 billion, and total loans increased 6.7% to $1.04 billion. The net interest margin was 3.66%. While on-balance sheet liquidity remained strong and tangible book value increased, non-accrual loans notably rose to $9.8 million. The company repurchased 100,000 shares and plans expansion into Ventura County.

374Water (SCWO) seeks shareholder approval for a reverse stock split (1-for-8 to 1-for-20) at a December 15, 2025 meeting. If approved, split-adjusted trading could begin December 26, 2025. The board can abandon the split even after approval. Management cites maintaining its Nasdaq listing and improving financing options. Recent insider purchases, a Minimum Equity Ownership Policy, and $7.0M from an ATM facility extending cash runway into Q2 2026 were also noted. A Q3 2025 results call is scheduled for November 12, 2025.

Western Alliance Bank is financing the Senator Joseph M. Neal Jr. Apartments, a 192-unit affordable housing project in North Las Vegas, scheduled to open in Fall 2027. The bank’s investment includes the purchase of tax-exempt bonds and tax credit equity. The community, named after Nevada’s first Black state senator, will feature one- and two-bedroom units with amenities and prioritize senior residents. The project addresses Las Vegas’s affordable housing shortage via a partnership between public and private sectors, offering units for residents earning below the area median income, with many benefiting from HUD Section 8 assistance.

K12 (LRN) received two Silver Medals at the 2025 International Serious Play Awards for its K12 ELA Village and K12 Coordinate Islands world for Minecraft Education. These games target grades 2-5, utilizing Science of Reading principles and standards-aligned gameplay to enhance English language arts and mathematics skills. K12 ELA Village focuses on grammar and vocabulary, while Coordinate Islands teaches graphing concepts. K12 has served over 3 million students, providing interactive and engaging learning experiences.

Cleghorn Minerals (OTC:CLGMF) reduced incentive stock options granted to Adelaide Capital Markets from 100,000 to 64,800, exercisable at $0.05 per share and expiring October 10, 2030. This adjustment complies with TSX Venture Exchange regulations. The revised option number reflects a possible recalibration of the advisory relationship, adoption of a conservative approach to potential advisory fees due to the performance of Cleghorn Mineral’s stock, or failure to meet initially agreed upon milestones. The long-term expiration indicates optimism regarding Cleghorn’s development prospects.